Breast Cancer Coverage from Every Angle
Advertisement
Advertisement


Mariana Chavez-MacGregor, MD, MSc: Clinical Rationale for Adding Everolimus to Adjuvant Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer

Posted: Thursday, December 8, 2022

Mariana Chavez-MacGregor, MD, MSc, of The University of Texas MD Anderson Cancer Center, discusses phase III findings of the SWOG S1207 trial on combining adjuvant everolimus with adjuvant endocrine therapy among patients with high-risk, hormoneĀ­ receptorā€“positive, HER2-negative early-stage breast cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.